Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Visser, J. Rake, P. Labrune, J. Leonard, S. Moses, K. Ullrich, U. Wendel, P. Smit (2002)
Consensus guidelines for management of glycogen storage disease type 1b – European Study on Glycogen Storage Disease Type 1European Journal of Pediatrics, 161
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib
J. Calderaro, P. Labrune, G. Morcrette, G. Morcrette, S. Rebouissou, S. Rebouissou, D. Franco, S. Prévôt, A. Quaglia, P. Bedossa, L. Libbrecht, L. Terracciano, G. Smit, P. Bioulac-Sage, J. Zucman‐Rossi, J. Zucman‐Rossi (2013)
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.Journal of hepatology, 58 2
F. White, Simon Jones (2011)
The use of continuous glucose monitoring in the practical management of glycogen storage disordersJournal of Inherited Metabolic Disease, 34
S. Iyer, Chao-Long Chen, Chi-Chih Wang, Shih‐Ho Wang, A. Concejero, Yueh-Wei Liu, Chin‐Hsiang Yang, C. Yong, B. Jawan, Yu-Fan Cheng, H. Eng (2007)
Long‐term results of living donor liver transplantation for glycogen storage disorders in childrenLiver Transplantation, 13
David Wang, Laurie Fiske, Caroline Carreras, D. Weinstein (2011)
Natural history of hepatocellular adenoma formation in glycogen storage disease type I.The Journal of pediatrics, 159 3
P. McKiernan (2006)
Metabolic disease as a cause of chronic liver disease in childrenCurrent Paediatrics, 16
P. Bioulac-Sage, H. Laumonier, G. Couchy, B. Bail, A. cunha, A. Rullier, C. Laurent, J. Blanc, Gaelle Cubel, H. Trillaud, J. Zucman‐Rossi, C. Balabaud, J. Saric (2009)
Hepatocellular adenoma management and phenotypic classification: The Bordeaux experienceHepatology, 50
S. Austin, A. Proia, Michele Spencer-Manzon, J. Butany, S. Wechsler, P. Kishnani (2012)
Cardiac Pathology in Glycogen Storage Disease Type III.JIMD reports, 6
P. Kishnani, S. Austin, P. Arn, D. Bali, A. Boney, L. Case, W. Chung, D. Desai, A. El-Gharbawy, R. Haller, G. Smit, Alastair Smith, L. Hobson‐Webb, S. Wechsler, D. Weinstein, Michael Watson, Michael Watson (2010)
Glycogen Storage Disease Type III diagnosis and management guidelinesGenetics in Medicine, 12
Christiaan Sentner, Irene Hoogeveen, David Weinstein, R. Santer, E. Murphy, Patrick McKiernan, U. Steuerwald, Nicholas Beauchamp, J. Taybert, P. Laforêt, François Petit, A. Hubert, P. Labrune, G. Smit, T. Derks (2016)
Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcomeJournal of Inherited Metabolic Disease, 39
Sing-Chung Li, Chiao-Ming Chen, J. Goldstein, Jer-Yuarn Wu, E. Lemyre, T. Burrow, P. Kang, Yuan-Tsong Chen, D. Bali (2010)
Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorderJournal of Inherited Metabolic Disease, 33
P. Kishnani, T. Chuang, D. Bali, D. Koeberl, S. Austin, D. Weinstein, E. Murphy, Ying‐Ting Chen, K. Boyette, Chu-Hao Liu, Yuan-Tsong Chen, Ling-Hui Li (2009)
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease.Human molecular genetics, 18 24
Susanne Boers, G. Visser, P. Smit, S. Fuchs (2014)
Liver transplantation in glycogen storage disease type IOrphanet Journal of Rare Diseases, 9
R. Selby, T. Starzl, E. Yunis, B. Brown, R. Kendall, A. Tzakis (1991)
Liver transplantation for type IV glycogen storage disease.The New England journal of medicine, 324 1
Haiqing Yi, E. Brooks, B. Thurberg, J. Fyfe, P. Kishnani, Baodong Sun (2014)
Correction of glycogen storage disease type III with rapamycin in a canine modelJournal of Molecular Medicine, 92
R. Beegle, Laurie Brown, D. Weinstein (2015)
Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I.JIMD reports, 18
F. Rajas, Julie Clar, A. Gautier-Stein, G. Mithieux (2015)
Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the diseaseJournal of Inherited Metabolic Disease, 38
María Adeva-Andany, M. González-Lucán, C. Donapetry-García, C. Fernández-Fernández, E. Ameneiros-Rodríguez (2016)
Glycogen metabolism in humans☆☆☆BBA Clinical, 5
Jing Wang, H. Cui, Ni‐Chung Lee, W. Hwu, Y. Chien, W. Craigen, L. Wong, V. Zhang (2012)
Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous originGenetics in Medicine, 15
N. Beauchamp, A. Dalton, U. Ramaswami, H. Niinikoski, K. Mention, P. Kenny, K. Kolho, J. Raiman, J. Walter, E. Treacy, S. Tanner, M. Sharrard (2007)
Glycogen storage disease type IX: High variability in clinical phenotype.Molecular genetics and metabolism, 92 1-2
P. Kishnani, S. Austin, J. Abdenur, P. Arn, D. Bali, A. Boney, W. Chung, A. Dagli, D. Dale, D. Koeberl, M. Somers, S. Wechsler, D. Weinstein, J. Wolfsdorf, M. Watson (2014)
Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and GenomicsGenetics in Medicine, 16
M. Khanna, S. Ramanathan, N. Fasih, N. Schieda, V. Virmani, M. McInnes (2015)
Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenomaInsights into Imaging, 6
Li-Ya Chiu, P. Kishnani, T. Chuang, C. Tang, Cheng-Yuan Liu, D. Bali, D. Koeberl, S. Austin, K. Boyette, D. Weinstein, E. Murphy, Adam Yao, Yuan-Tsong Chen, Ling-Hui Li (2014)
Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkersJournal of Gastroenterology, 49
S. Willot, V. Marchand, A. Rasquin, F. Alvarez, Steven Martin (2010)
Systemic progression of type IV glycogen storage disease after liver transplantation.Journal of pediatric gastroenterology and nutrition, 51 5
Michael Davis, P. Rufo, Steven Polyak, David Weinstein (2008)
Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type IbJournal of Inherited Metabolic Disease, 31
T. Derks, G. Smit (2015)
Dietary management in glycogen storage disease type III: what is the evidence?Journal of Inherited Metabolic Disease, 38
L. Oterdoom, Evelyne Verweij, K. Biermann, M. Langeveld, H. Buuren (2015)
Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease.Journal of gastrointestinal and liver diseases : JGLD, 24 4
Luis Franco, V. Krishnamurthy, D. Bali, D. Weinstein, P. Arn, B. Clary, A. Boney, J. Sullivan, D. Frush, Yuan-Tsong Chen, P. Kishnani (2005)
Hepatocellular carcinoma in glycogen storage disease type Ia: A case seriesJournal of Inherited Metabolic Disease, 28
Haiqing Yi, Fengqin Gao, S. Austin, P. Kishnani, Baodong Sun (2016)
Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IVMolecular Genetics and Metabolism Reports, 9
Purpose of the Review The purpose of this study is to review nificantly improved their outcome and improved metabolic the pathobiology of the hepatic glycogen storage diseases control can prevent many long-term complications. (GSD) and recent developments in their management. Recent Findings Increasingly, noninvasive mutation detec- Keywords Glycogen storage disease Inherited metabolic . . . tion has replaced biological and tissue samples as the first disorder Dietary treatment Metabolic control Hepatic . . line diagnostic method. For type 1 GSD, continuous sub- adenomata Hepatocellular carcinoma Liver transplantation cutaneous monitoring has transformed patient monitoring. There is evidence that improved metabolic control can prevent complications such as adenoma formation and Introduction renal dysfunction. Improved understanding of the patho- physiology of hepatic adenomata may allow rationaliza- Short-term blood glucose control is mediated by the liver via tion of their management. Hepatocellular carcinoma only glucose-6-phosphate (G6P). Postprandially, the liver imports develops in established adenomata, offering an option for glucose to form G6P which is used for glycogen synthesis. prevention. For type 111 GSD, intrinsic liver disease and The process is then reversed resulting in hepatic glucose ex- myopathy become the major clinical concerns after child- port by dephosphorylation of G6P by glucose-6-phosphatase hood.
Current Pathobiology Reports – Springer Journals
Published: Jun 6, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.